Form 8-K - Current report:
SEC Accession No. 0001437749-19-001640
Filing Date
2019-02-01
Accepted
2019-02-01 08:01:21
Documents
2
Period of Report
2019-01-28
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K navb20190131_8k.htm 8-K 22736
2 EXHIBIT 99.1 ex_133775.htm EX-99.1 9838
  Complete submission text file 0001437749-19-001640.txt   33872
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

EIN.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35076 | Film No.: 19557752
SIC: 2835 In Vitro & In Vivo Diagnostic Substances